The estimated Net Worth of Ginger Gregory is at least $671 Thousand dollars as of 1 August 2019. Ginger Gregory owns over 179 units of Biogen stock worth over $670,553 and over the last 8 years he sold BIIB stock worth over $0. In addition, he makes $0 as Chief Human Resource Officer and Executive Vice President at Biogen.
Ginger Gregory BIIB stock SEC Form 4 insider trading
Ginger has made over 4 trades of the Biogen stock since 2013, according to the Form 4 filled with the SEC. Most recently he exercised 179 units of BIIB stock worth $52,300 on 1 August 2019.
The largest trade he’s ever made was exercising 32,500 units of Biogen stock on 30 April 2013 worth over $994,500. On average, Ginger trades about 4,347 units every 286 days since 2012. As of 1 August 2019 he still owns at least 2,295 units of Biogen stock.
You can see the complete history of Ginger Gregory stock trades at the bottom of the page.
Ginger Gregory biography
Dr. Ginger Gregory, Ph.D. is Chief Human Resource Officer, Executive Vice President of Biogen Inc. since July 2017. Prior to joining Biogen, Dr. Gregory served as Executive Vice President and Chief Human Resources Officer at Shire PLC, a global specialty biopharmaceutical company, from February 2014 to April 2017. Prior to that, Dr. Gregory held executive-level human resources positions for several multinational companies across a variety of industries, including Dunkin’ Brands Group Inc., a restaurant holding company, where she served as Chief Human Resource Officer; Novartis, AG, a pharmaceutical company, where she was the division head of Human Resources for Novartis Vaccines and Diagnostics, Novartis Consumer Health and Novartis Institutes of BioMedical Research from 2005 to 2012; and Novo Nordisk A/S, a pharmaceutical company, where she served as Senior Vice President, Corporate People & Organization at the company’s headquarters in Copenhagen, Denmark. Earlier in her career, Dr. Gregory held a variety of human resources generalist and specialist positions at BMS, a pharmaceutical company, and served as a consultant with Booz Allen & Hamilton, an information technology consulting company, in the area of organization change and effectiveness.
How old is Ginger Gregory?
Ginger Gregory is 51, he’s been the Chief Human Resource Officer and Executive Vice President of Biogen since 2017. There are 17 older and 3 younger executives at Biogen. The oldest executive at Biogen, Inc. is Lynn Schenk, 74, who is the Independent Director.
What’s Ginger Gregory’s mailing address?
Ginger’s mailing address filed with the SEC is BIOGEN INC., 225 BINNEY ST., CAMBRIDGE, MA, 02142.
Insider trading at Biogen
Over the last 16 years, insiders at Biogen have traded over $156,919,925 worth of Biogen stock and bought 660,866 units worth $181,912,701 . The most active insider traders include Alexander J Denner, Stelios Papadopoulos, and George A Scangos. On average, Biogen executives and independent directors trade stock every 9 days with the average trade being worth of $3,890,229. The most recent stock trade was executed by Ginger Gregory on 1 August 2019, trading 179 units of BIIB stock currently worth $51,731.
What does Biogen do?
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. It offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA, and FAMPYRA for the treatment of multiple sclerosis; SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.
What does Biogen’s logo look like?
Complete history of Ginger Gregory stock trades at Biogen and Dunkin’ Brands
Biogen executives and stock owners
Biogen executives and other stock owners filed with the SEC include:
- Michel Vounatsos, Chief Executive Officer, Director
- Alfred Sandrock, Executive Vice President, Chief Medical Officer
- Michael Ehlers, Executive Vice President, Research and Development
- Susan Alexander, Executive Vice President, Chief Legal Officer and Secretary
- Jeffrey Capello, Chief Financial Officer, Executive Vice President
- Stelios Papadopoulos, Independent Chairman of the Board
- Robert Pangia, Independent Director
- Brian Posner, Independent Director
- Lynn Schenk, Independent Director
- Stephen Sherwin, Independent Director
- Alexander Denner, Independent Director
- Caroline Dorsa, Independent Director
- Eric Rowinsky, Independent Director
- Richard Mulligan, Independent Director
- Nancy Leaming, Independent Director
- Jesus Mantas, Director
- William Hawkins, Director
- John Chiminski, Director
- Robin Kramer, Chief Accounting Officer, Vice President
- Daniel Karp, Executive Vice President, Corporate Development
- Chirfi Guindo, Executive Vice President, Head of Global Marketing, Market Access and Customer Innovation
- Ginger Gregory, Chief Human Resource Officer, Executive Vice President
- George A Scangos, Chief Executive Officer
- Adriana Karaboutis, EVP, Tech. and Bus. Solutions
- Gregory F Covino, VP, Chief Accounting Officer
- Paul Mc Kenzie, EVP Pharmaceutical Oper & Tech
- Paul J Clancy, CFO
- Kenneth Di Pietro, EVP Human Resources
- Adam Koppel, SVP, Chief Strategy Officer
- Jean Paul Kress, EVP Pres Int’l & Global Hd GTO
- Phillip A Sharp, Director
- Steven H Holtzman, EVP Corp Devel and Strategy
- John Cox, EVP Pharmaceutical Oper & Tech
- Spyridon Artavanis Tsakonas, SVP, Chief Scientific Officer
- William Young, Director
- Raymond Pawlicki, SVP, Chief Information Officer
- Stuart A Kingsley, EVP, Global Comm. Operations
- Douglas E Williams, EVP Research & Development
- Craig Eric Schneier, EVP, Human Resources
- Robert E. Gagnon, Chief Acct Officer VP & Contr
- Francesco Granata, EVP Global Commercial Operatio
- James C Mullen, CEO and President
- Michael F Mac Lean, SVP, Chief Accounting Officer
- Bruce Ross, Director
- Robert A Hamm, SVP, Immunology Business Unit
- Cecil B Pickett, President, R & D
- Marijn E Dekkers, Director
- Lawrence C Best, Director
- Faheem Hasnain, SVP, Oncology SBU
- Hans Peter Hasler, SVP, International
- Mark C Wiggins, EVP – Business Development
- Michael Lytton, EVP Corporate & Business Devel
- Alan Glassberg, Director
- John Michael Dunn, EVP – New Ventures
- Michael Gilman, EVP – Research
- Thomas J Bucknum, EVP. General Counsel, Sec.
- Nabil Hanna, EVP, Research
- William H Rastetter, Executive Chairman
- William R Rohn, Exec VP & COO
- Sylvie L Gregoire, EVP, Bus. Dev & Program Mgmt.
- Burt A Adelman, EVP, Development
- Alan Belzer, Director
- Michael Kowolenko, SVP, Pharm Ops & Technology
- Peter N Kellogg, Executive Vice President, CFO
- Mary L Good, Director
- Thomas F Keller, Director
- Connie Matsui, Sr V P, Planning& Resource Dev







